Feb 6, 2020 | Densitas Inc., News
Halifax-based Densitas, whose software helps assess the density of breasts during mammograms, has announced that Prince Edward Island has become the second province, after Nova Scotia, to integrate its software across its screening program.
The Densitas software — named Densitas densityai — provides an automated mechanism for quantifying and recording breast tissue density, a risk factor for breast cancer in women. Dense breasts can mask cancerous cells. Dense breast tissue is also linked to higher chances of cancer.
Now, every woman who receives a screening mammogram on P.E.I. will be notified of her breast density through the company’s densityai algorithm.
“Our advanced solutions are built to solve real clinical problems and effectively support healthcare providers,” said Ryan Duggan, Director of Product Development at Densitas in a statement.
The Densitas platform comprises three different products that tackle challenges in breast cancer screening, including mammography quality, workflow efficiencies, compliance with national standards, and meeting accreditation requirements.
Feb 15, 2019 | Densitas Inc., News
Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.
See full article here
Nov 13, 2018 | Densitas Inc., News
PRNewswire/ – Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform.
“The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers” says Mohamed Abdolell, CEO of Densitas. “We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure.”
The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Blackford CEO, Ben Panter said this of the alliance:
“We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained.”
densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall.
To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364.
About Densitas:
Densitas’ vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit.
About Blackford
Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com
Contact Information:
Media Contact Densitas:
Alex Morris
[email protected]
647-470-4363
Media Contact Blackford:
Greg Kingston
[email protected]
+44 131 6688 411]]>
Jul 25, 2018 | Densitas Inc., News
Will enable mammography quality improvement and population level stratified breast screening.
HALIFAX, NS., Canada, July 24, 2018 /PRNewswire/ ‑ Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, announces a recently formalized partnership with the Leeds Teaching Hospitals NHS Trust in the UK. The partnership seeks to introduce innovative personalized breast screening technologies, including our DENSITAS|density™ and DENSITAS|quality™ products, into routine clinical workflow. The goal is to ultimately enable population level stratified breast screening and mammography quality improvement and stimulate research in the area of breast health.
“Our partnership with Leeds Teaching Hospitals, NHS Trust is the first of its kind in the UK and represents an alignment of vision that is intended to improve appropriateness of care in breast cancer screening through innovation in technology and service delivery,” says Mohamed Abdolell, CEO of Densitas. “We are excited to collaborate with Dr. Nisha Sharma, Director of Breast Screening, and her team at Leeds Teaching Hospital’s NHS Trust breast screening program to introduce our machine learning powered breast imaging analytics platform into a clinical care setting.”
Breast tissue density is a confirmed independent risk factor for breast cancer in women. The current standard of care in the UK National Health Service is subjective, visual assessment of breast tissue density by the radiologist, if it is performed at all. The Densitas|density™ software provides an automated mechanism for quantifying and recording breast density, and making it readily available to the radiologist, along with the digital mammograms. This will allow the Leeds team to assess breast density for every woman who has a screening mammogram performed. Beyond speeding and simplifying the process of quantifying breast density, Densitas|density™ standardizes the density measurement and enables stratification of screen eligible women to ensure those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Dr Sharma said: “This is a really exciting development for us because it has the potential to make a real difference to the quality of our screening program and ultimately to the health outcomes of women in Leeds. I’m very pleased that the Leeds Breast Screening unit and research team have the opportunity to collaborate with Densitas. This is the foundation for future developments that will improve breast care, so it’s excellent news for women.”
About Densitas:
Densitas, Inc. develops advanced breast imaging analytics technologies powered by machine learning. Our goal is to deliver actionable insights at the point-of-care that improve the quality of breast health management. Our products address the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health
